Friedmann P S, Rees J, White S I, Matthews J N
Dermatology Department, University of Newcastle upon Tyne, England.
Clin Exp Immunol. 1990 Sep;81(3):507-9. doi: 10.1111/j.1365-2249.1990.tb05364.x.
We examined the effects of a small initial sensitizing dose of antigen (dinitrochlorobenzene, DNCB) on the subsequent response to a second, defined sensitizing stimulus. The second stimulus was actually the regimen of four doses of DNCB (3.125, 6.25, 12.5, and 25 micrograms) normally used as the elicitation challenge. In two separate experiments 13 and 18 control subjects received an initial 'challenge' with the four doses to induce sensitivity, and 4 weeks later their responses were determined with a second, elicitation challenge. Two groups of 12 and 15 experimental subjects received an initial dose predicted to induce clinically detectable sensitivity in 50% or 25%, respectively. Four weeks later, their responsiveness was determined with quantitative challenge and the subjects who gave no response received a further challenge 4 weeks later. Their responses, compared with those from the control subjects, were augmented, indicating that sub-clinical priming of the immune system had indeed occurred.
我们研究了小剂量初始致敏抗原（二硝基氯苯，DNCB）对后续针对第二次明确致敏刺激的反应的影响。第二次刺激实际上是通常用作激发挑战的四剂DNCB（3.125、6.25、12.5和25微克）方案。在两项独立实验中，13名和18名对照受试者接受了四剂初始“挑战”以诱导敏感性，4周后通过第二次激发挑战确定他们的反应。两组分别为12名和15名实验受试者，分别接受了预计可诱导50%或25%临床可检测敏感性的初始剂量。4周后，通过定量挑战确定他们的反应性，无反应的受试者在4周后接受进一步挑战。与对照受试者的反应相比，他们的反应增强了，这表明免疫系统确实发生了亚临床启动。
